DSpace logo

Please use this identifier to cite or link to this item: http://dspace.bits-pilani.ac.in:8080/jspui/xmlui/handle/123456789/3513
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBajaj, Kiran-
dc.date.accessioned2021-11-11T11:24:28Z-
dc.date.available2021-11-11T11:24:28Z-
dc.date.issued2005-07-01-
dc.identifier.urihttps://www.sciencedirect.com/science/article/pii/S0968089605003160?via%3Dihub-
dc.identifier.urihttp://dspace.bits-pilani.ac.in:8080/xmlui/handle/123456789/3513-
dc.description.abstractVariety of N-(4-phenyl-3-(2′,3′,4′(un)substituted phenyl)thiazol-2(3H)-ylidene)-2,4(un)substituted acridin-9-amine (4a–o) and 1-[(2,4-(un)substituted acridin-9-yl)-3-(4-phenyl-3-(2′,3′,4′(un)substituted phenyl)thiazol-2(3H)-ylidene)]isothiourea (5a–h) derivatives have been synthesized by condensation of 4-phenyl-3-(2′,3′,4′(un)substituted phenyl)thiazol-2(3H)-imine (3a–g) with 9-chloro-2,4-(un)substituted acridine (1a–c) and 9-isothiocyanato-2,4-(un)substituted acridine (2a–d), respectively. All these compounds were characterized by correct 1H NMR, FT-IR, MS and elemental analyses. These compounds were screened for anti-inflammatory, analgesic and kinase (CDK1, CDK5 and GSK3) inhibition activities. Some compounds exhibited good anti-inflammatory (25–32%) and potent analgesic (50–75%) activities, at 50 mg/kg p.o. A compound, 4o (R1 = H, R2 = OCH3, R3 = CH3, R4 = CH3, R5 = H) exhibited moderate CDK1 (IC50 = 8.5 μM) inhibition activity.en_US
dc.language.isoenen_US
dc.publisherElsieveren_US
dc.subjectChemistryen_US
dc.subjectSynthesisen_US
dc.subjectAcridinyl-thiazolino derivativesen_US
dc.subjectAnti-inflammatoryen_US
dc.subjectAnalgesicen_US
dc.subjectCDK1 inhibitoren_US
dc.titleSynthesis of acridinyl-thiazolino derivatives and their evaluation for anti-inflammatory, analgesic and kinase inhibition activitiesen_US
dc.typeArticleen_US
Appears in Collections:Department of Chemistry

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.